Please assess the completion status of the following clinical trial:

Trial Title: The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* MPH naïve~* recent ICD-10 diagnosis of hyperkinetic disorder (F90.0-90.9) or attention deficit disorder without hyperactivity (F98.8)~* clinical indication for treatment with IR-MPH~Exclusion Criteria:~* mental retardation (ICD-F70.X or IQ \< 70)~* previous treatment with drugs metabolised by carboxylesterase 1 (CES1)~* severe comorbid psychiatric or somatic disease that resulted in contraindication for treatment with MPH~* language barriers~* lack of informed consent.~Specific additional exclusion criteria for genetic analyses:~* Non-caucasian~* Lack of DNA~* Consanguine patients~* Variants with a minor allele frequency (MAF) above 0.05 or not in Hardy-Weinberg equilibrium

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- ADHD patients (Type: None): Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).